VanEck Pharmaceutical ETF
PPH
48 hedge funds and large institutions have $40.9M invested in VanEck Pharmaceutical ETF in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
14% more funds holding
Funds holding: 42 → 48 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $41M → $40.9M (-$139K)
2.08% less ownership
Funds ownership: 17.35% → 15.27% (-2.1%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.71M |
| 2 |
JP Morgan Chase
New York
|
+$776K |
| 3 |
CNB
City National Bank
Beverly Hills,
California
|
+$299K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$296K |
| 5 |
CCT
Country Club Trust
Kansas City,
Missouri
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$6.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$899K |
| 3 |
HR
Howe & Rusling
Rochester,
New York
|
-$568K |
| 4 |
AWM
Altavista Wealth Management
Asheville,
North Carolina
|
-$201K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$167K |
PPH Hedge Fund Activity: Q4 2013 in Review
48 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2013, worth a combined $40.9M — down 0.34% from $41M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PPH positions and 4 closed out — a net gain of 6 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Bank of America, adding an estimated $1.71M. The largest seller was Credit Suisse, cutting an estimated $6.03M.
- 48 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2013, up from 42 in Q3 2013.
- Funds reported $40.9M of VanEck Pharmaceutical ETF stock for Q4 2013, down 0.34% quarter-over-quarter.
- 10 funds opened new VanEck Pharmaceutical ETF positions in Q4 2013 and 4 closed out, a net change of +6 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2013 was Bank of America, an estimated $1.71M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2013 was Credit Suisse, an estimated $6.03M sold.
Based on aggregated 13F filings for Q4 2013.